
Asceletis’ muscle-preserving weight loss therapy sustains 40-day half-life
Ascletis Pharma’s Phase Ib trial examining its adipose-targeted muscle-preserving weight loss candidate has been able to show a half-life of up to 26 days and 40 days in volunteers with high cholesterol and patients with obesity, respectively. The Hong …